Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 11/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | BCR | P11274 | 4/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12397276 | 0.95 | ABL1 (0.40) | BRAFABL1BCRABCG2GPR142 | |
| SCHEMBL12397366 | 0.94 | ABL1 (0.40) | BRAFABL1BCRABCG2GPR142 | |
| SCHEMBL12397370 | 0.94 | ABL1 (0.39) | BRAFABL1BCRABCG2GPR142 | |
| SCHEMBL12397028 | 0.94 | BRAF (0.47) | BRAFABL1BCRGPR142 | |
| SCHEMBL12397262 | 0.92 | BRAF (0.37) | BRAFABL1BCRABCG2GPR142 | |
| SCHEMBL12464937 | 0.88 | ABCG2 (0.40) | BRAFABL1BCRABCG2GPR142 | |
| SCHEMBL12397039 | 0.88 | BRAF (0.44) | BRAFABL1BCRGPR142 | |
| SCHEMBL12396946 | 0.88 | BRAF (0.44) | BRAFABL1BCRGPR142 | |
| SCHEMBL12397034 | 0.88 | BRAF (0.46) | BRAFABL1BCRGPR142 | |
| SCHEMBL12397018 | 0.87 | GPR142 (0.45) | BRAFABL1BCRGPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889665-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183952-A1 | NEW CHEMICAL COMPOUNDS | MKI67, CCNA1, CCNT1 | BRAF 525/4885ABL1 136/4885BCR 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.